<DOC>
	<DOCNO>NCT01375907</DOCNO>
	<brief_summary>The purpose study evaluate safety Rotavin-M1 produce Center Research Production Vaccines Biologicals ( POLYVAC ) adult volunteer Vietnam .</brief_summary>
	<brief_title>Safety Study Rotavirus Vaccine ( Rotavin-M1 ) Among Healthy Adults</brief_title>
	<detailed_description>Rotavirus ( RV ) important cause acute gastroenteritis child worldwide . In Vietnam rotavirus cause estimate 122,000-140,000 hospitalization 2900-5400 death per year among child 5 year age ( 1 ) . Over past 13 year , sentinel hospital surveillance identify rotavirus 44 % -62 % child admit treatment acute diarrhea Vietnam ( 2-4 ) . Such high burden disease justify accelerate development new locally manufacture vaccine rotavirus Vietnam . It estimate vaccine introduce current childhood immunization schedule , could reduce severe rotavirus disease 60 % give current vaccine efficacy coverage ( 5 ) . The Government Vietnam pursue policy encourage local vaccine production country could self-reliant affordable vaccine population ( 6 ) . Over past decade , several locally produce vaccine poliomyelitis , cholera , Japanese encephalitis , Diphtheria-Pertussis-Tetanus contribute reduction prevalence diseases eradication polio past decade . While two commercial rotavirus vaccine , RotarixTM ( GSK , Belgium ) RotaTeqÂ® ( Merck ) , test Vietnam , neither currently available affordable cost national program . Therefore , candidate vaccine , Rotavin-M1 , develop order fill need affordable vaccine Vietnamese child ( 6 ) . This vaccine similar RotarixTM , develop select common G1P [ 8 ] strain attenuate serial</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>At dose 1 Healthy male female , 18 40 year age , Free disease , Written inform consent obtain subject . At dose 2 Received dose 1 . Oral inform consent obtain subject continue participate study . At dose 1 1 . Pregnant woman plan pregnant study period . 2 . Has chronic disease ( cardiovascular , liver , kidney disease ) . 3 . Acute disease time enrolment . 4 . Administering corticosteroid ( &gt; 1mg/kg/day ) . 5 . Received immunosuppressive therapy within 4 week vaccination ( Administration immunoglobulins and/or blood product corticosteroid &gt; 2 week ) . 6 . Immunosuppressive immunodeficient condition . 7 . Allergic reaction component vaccine , include anaphylactic shock antibiotic . 8 . Fever ( axillary temperature &gt; 38oC ) within 3 day day vaccination . 9 . Has type blood disorder , leukemia , malignant tumor affect bone marrow lymph system . 10 . Use investigational nonregistered product ( unlicensed drug vaccine ) study vaccine study period . At dose 2 1 . Pregnant woman plan pregnant next 1 month . 2 . Acute disease time 2nd dose . 3 . Administering corticosteroid ( &gt; 1mg/kg/day ) . 4 . Received immunosuppressive therapy within 4 week vaccination ( administration immunoglobulins and/or blood product corticosteroid &gt; 2 week ) . 5 . Immunosuppressive immunodeficient condition . 6 . History allergic disease reaction likely exacerbate component study vaccine . 7 . Fever ( axillary temperature &gt; 38oC ) within 3 day day vaccination . 8 . Has type blood disorder , leukemia , malignant tumor affect bone marrow lymph system . 9 . Use investigational nonregistered product ( unlicensed drug vaccine ) study vaccine study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>blood cell count</keyword>
	<keyword>BUN</keyword>
	<keyword>ALT</keyword>
	<keyword>AST</keyword>
	<keyword>diarrhea</keyword>
	<keyword>fever</keyword>
	<keyword>vomit</keyword>
	<keyword>nausea</keyword>
	<keyword>loss appetite</keyword>
	<keyword>irritability</keyword>
</DOC>